Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143466 · ClinicalTrials.gov registry record · Phase 1
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
A Phase 1 study of Advanced Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 344
- Enrollment target
- 20
- Study locations
NCT02143466: Active Phase 1 study of Advanced Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.
NCT02143466 is a Phase 1 study of Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 344 participants, roughly in line with the 367-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02143466, a Phase 1 study of Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 344 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
Primary Outcome
Part A: To investigate the safety and tolerability of AZD9291 when given in combination with AZD6094 or selumetinib who have progressed following prior therapy with an EGFR TKI agent, and define the combination dose(s) for further clinical evaluation.
Conditions Studied
Interventions
- DRUG Part A - AZD9291 in combination with AZD6094
- DRUG Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
- DRUG Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- DRUG Part A - AZD9291 in combination with intermittent selumetinib
- DRUG Part A - AZD9291 in combination with MEDI4736
Study Locations (20)
Other
- Research Site - Chūōku
- Research Site - Habikino-shi
- Research Site - Hirakata-shi
- Research Site - Kashiwa
- Research Site - Nagoya
- Research Site - Nagoya
- Research Site - Gdansk
- Research Site - Krakow
- Research Site - Olsztyn
- Research Site - Poznan
- Research Site - Warsaw
- Research Site - Chelyabinsk
Massachusetts
- Research Site - Boston
- Research Site - Boston
Alberta
- Research Site - Calgary
- Research Site - Edmonton
Georgia
- Research Site - Atlanta
New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2014-08-05 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT02143466 still lists
NCT02143466 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 367-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target.
The record links to 1 condition, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Part A - AZD9291 in combination with AZD6094 is the first listed.
NCT02143466 names 20 study sites across 7 states, led by Other, Massachusetts, Alberta.
Frequently Asked Questions
What is clinical trial NCT02143466 about?
NCT02143466 is a clinical study titled "AZD9291 in Combination With Ascending Doses of Novel Therapeutics". The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
What is the current status of trial NCT02143466?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 344 participants. The study started on 2014-08-05. Estimated completion is 2026-12-31.
What conditions does trial NCT02143466 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT02143466?
The interventions under investigation include: Part A - AZD9291 in combination with AZD6094 (DRUG), Part A - AZD9291 in combination with continuous selumetinib (Asian subjects) (DRUG), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects) (DRUG), Part A - AZD9291 in combination with intermittent selumetinib (DRUG), Part A - AZD9291 in combination with MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02143466?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02143466 being conducted?
This trial has 20 study locations across Georgia, Massachusetts, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02143466's enrollment target sits among peer trials
344 11th of 22 higher than 12 of 22 other Advanced Non-Small-Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Non-Small-Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ACTIVE NOT RECRUITING · Phase 1
-
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
COMPLETED · Phase 1
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI